Experience with tranexamic acid, an indirect fibrinolytic inhibitor, started as soon as it was
released from Shosuke Okamoto's lab in the early 1960s. It was first prescribed to females …

Perioperative bleeding and postsurgical hemorrhage are common in invasive surgical
procedures, including orthopedic surgery. Tranexamic acid (TXA) is a pharmacologic agent …

Objective: The aim of this study is critically to review the available evidence regarding the
use, efficacy and safety of tranexamic acid in the management of hemorrhage during …

Among the various pharmacological options to decrease peri-operative bleeding,
tranexamic acid appears to be one of the most interesting. Several trials have consistently …

Abstract Purpose In this Continuing Professional Development module, we review the
practical pharmacology of tranexamic acid and its clinical use in trauma, obstetrics, and …

There has been an explosion of interest in the ability of tranexamic acid to reduce morbidity
and mortality in surgical and traumatic bleeding. Tranexamic acid has been shown to reduce …

Tranexamic acid is a fibrinolytic inhibitor which reduces blood loss in total knee
replacement. We examined the effect on blood loss of a standardised intravenous bolus …

Intravenous tranexamic acid (TXA) reduces death because of bleeding in patients with
trauma and postpartum haemorrhage. However, in some settings intravenous injection is not …

Background Many different doses and administration schemes have been proposed for the
use of the antifibrinolytic drug tranexamic acid during cardiac surgery. This study evaluated …

Background The antifibrinolytic agent tranexamic acid (TXA) is widely used for the
prevention and treatment of hyperfibrinolytic states, such as in severe polytrauma. It can also …